Your browser doesn't support javascript.
loading
The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis.
Said, Samar M; Best Rocha, Alejandro; Valeri, Anthony M; Paueksakon, Paisit; Dasari, Surendra; Theis, Jason D; Vrana, Julie A; Obadina, Modupe O; Saghafi, Darius; Alexander, Mariam Priya; Sethi, Sanjeev; Larsen, Christopher P; Joly, Florent; Dispenzieri, Angela; Bridoux, Frank; Sirac, Christophe; Leung, Nelson; Fogo, Agnes B; McPhail, Ellen D; Nasr, Samih H.
Afiliación
  • Said SM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Best Rocha A; Arkana Laboratories, Little Rock, Arkansas, USA.
  • Valeri AM; Division of Nephrology, Columbia University Medical Center, New York, New York, USA.
  • Paueksakon P; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Dasari S; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
  • Theis JD; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Vrana JA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Obadina MO; Bethel Medical Clinic, Greenbelt, Maryland, USA.
  • Saghafi D; Allegheny Valley Hospital, Natrona Heights, Pennsylvania, USA.
  • Alexander MP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Sethi S; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Larsen CP; Arkana Laboratories, Little Rock, Arkansas, USA.
  • Joly F; Department of Nephrology, Dialysis and Renal Transplantation, University Hospital of Poitiers, French Reference Center for AL Amyloidosis, Poitiers, France.
  • Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Bridoux F; Department of Nephrology, Dialysis and Renal Transplantation, University Hospital of Poitiers, French Reference Center for AL Amyloidosis, Poitiers, France.
  • Sirac C; Department of Immunology, Joint Research Unit CNRS 7276, INSERM 1262, University of Limoges, French Reference Center for AL Amyloidosis, University Hospital Dupuytren, Limoges, France.
  • Leung N; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Fogo AB; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • McPhail ED; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Nasr SH; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: nasr.samih@mayo.edu.
Kidney Int ; 101(1): 152-163, 2022 01.
Article en En | MEDLINE | ID: mdl-34767832
ABSTRACT
The type of monoclonal light chain nephropathy is thought to be largely a function of the structural and physiochemical properties of light chains; hence most affected patients have only one light chain kidney disease type. Here, we report the first series of kidney light chain deposition disease (LCDD) concomitant with light chain amyloidosis (LCDD+AL), with or without light chain cast nephropathy (LCCN). Our LCDD+AL cohort consisted of 37 patients (54% females, median age 70 years (range 40-86)). All cases showed Congo red-positive amyloid deposits staining for one light chain isotype on immunofluorescence (62% lambda), and LCDD with diffuse linear staining of glomerular and tubular basement membranes for one light chain isotype (97% same isotype as the amyloidogenic light chain) and ultrastructural non-fibrillar punctate deposits. Twelve of 37 cases (about 1/3 of patients) had concomitant LCCN of same light chain isotype. Proteomic analysis of amyloid and/or LCDD deposits in eight revealed a single light chain variable domain mutable subgroup in all cases (including three with separate microdissections of LCDD and amyloid light chain deposits). Clinical data on 21 patients showed proteinuria (100%), hematuria (75%), kidney insufficiency and nephrotic syndrome (55%). Extra-kidney involvement was present in 43% of the patients. Multiple myeloma occurred in 68% (about 2/3) of these patients; none had lymphoma. On follow up (median 16 months), 63% developed kidney failure and 56% died. The median kidney and patient survivals were 12 and 32 months, respectively. LCDD+AL mainly affected patients 60 years of age or older. Thus, LCDD+AL could be caused by two pathological light chains produced by subclones stemming from one immunoglobulin light chain lambda or kappa rearrangement, with a distinct mutated complementary determining region.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Amiloidosis / Enfermedades Renales / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Kidney Int Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Amiloidosis / Enfermedades Renales / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Kidney Int Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos